Risk Factors for SARS-CoV-2 Infection and Severe Outcomes Among People With Human Immunodeficiency Virus: Cohort Study

Abstract Background Studies on COVID-19 in people with HIV (PWH) have had limitations. Further investigations on risk factors and outcomes of SARS-CoV-2 infection among PWH are needed. Methods This retrospective cohort study leveraged the national OPTUM COVID-19 data set to investigate factors associated with SARS-CoV-2 positivity among PWH and risk factors for severe outcomes, including hospitalization, intensive care unit stays, and death. A subset analysis was conducted to examine HIV-specific variables. Multiple variable logistic regression was used to adjust for covariates. Results Of 43 173 PWH included in this study, 6472 had a positive SARS-CoV-2 result based on a polymerase chain reaction test or antigen test. For PWH with SARS-CoV-2 positivity, higher odds were found for those who were younger (18–49 years), Hispanic White, African American, from the US South, uninsured, and a noncurrent smoker and had a higher body mass index and higher Charlson Comorbidity Index. For PWH with severe outcomes, higher odds were identified for those who were SARS-CoV-2 positive, older, from the US South, receiving Medicaid/Medicare or uninsured, a current smoker, and underweight and had a higher Charlson Comorbidity Index. In a subset analysis including PWH with HIV care variables (n = 5098), those with unsuppressed HIV viral load, a low CD4 count, and no antiretroviral therapy had higher odds of severe outcomes. Conclusions This large US study found significant ethnic, racial, and geographic differences in SARS-CoV-2 infection among PWH. Chronic comorbidities, older age, lower body mass index, and smoking were associated with severe outcomes among PWH during the COVID-19 pandemic. SARS-CoV-2 infection was associated with severe outcomes, but once we adjusted for HIV care variables, SARS-CoV-2 was no longer significant; however, low CD4 count, high viral load, and lack of antiretroviral therapy had higher odds of severe outcomes.

[1]  T. Perl,et al.  Incidence and Risk Factors for Severe Outcomes in Pediatric Patients With COVID-19. , 2023, Hospital pediatrics.

[2]  M. Parczewski,et al.  Non-HIV-related comorbidities and uncontrolled HIV replication are independent factors increasing the odds of hospitalization due to COVID-19 among HIV-positive patients in Poland , 2022, Infection.

[3]  M. Saag,et al.  Racial and ethnic disparities in coronavirus disease 2019 disease incidence independent of comorbidities, among people with HIV in the United States , 2022, AIDS.

[4]  N. Ford,et al.  Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO Global Clinical Platform of COVID-19 , 2022, The Lancet HIV.

[5]  Richard D Moore,et al.  Factors Associated With Severity of COVID-19 Disease in a Multicenter Cohort of People With HIV in the United States, March–December 2020 , 2022, Journal of acquired immune deficiency syndromes.

[6]  P. Nowak,et al.  Incidence and severity of COVID‐19 in adults with and without HIV diagnosis , 2022, Journal of internal medicine.

[7]  J. Skarbinski,et al.  SARS-CoV-2 Testing and Positivity Among Persons With and Without HIV in 6 US Cohorts , 2022, Journal of acquired immune deficiency syndromes.

[8]  J. Yombi,et al.  Outcomes of patients with HIV and COVID-19 co-infection: a systematic review and meta-analysis , 2022, AIDS Research and Therapy.

[9]  Karan Varshney,et al.  Risk Factors for COVID-19 Mortality Among People Living with HIV: A Scoping Review , 2022, AIDS and Behavior.

[10]  J. Skarbinski,et al.  COVID-19 infections post-vaccination by HIV status in the United States , 2021, medRxiv.

[11]  Richard D Moore,et al.  Factors associated with severity of COVID-19 disease in a multicenter cohort of people with HIV in the United States, March-December 2020 , 2021, medRxiv : the preprint server for health sciences.

[12]  Miguel Ángel Martínez,et al.  Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study , 2021, The Lancet HIV.

[13]  K. Crandall,et al.  Associations between HIV infection and clinical spectrum of COVID-19: a population level analysis based on US National COVID Cohort Collaborative (N3C) data , 2021, The Lancet HIV.

[14]  Christine S. Smedley,et al.  Risk factors for COVID-19-related in-hospital mortality in a high HIV and tuberculosis prevalence setting in South Africa: a cohort study , 2021, The Lancet HIV.

[15]  K. Crandall,et al.  COVID-19 Disease Severity among People with HIV Infection or Solid Organ Transplant in the United States: A Nationally-representative, Multicenter, Observational Cohort Study , 2021, medRxiv.

[16]  K. Bhaskaran,et al.  HIV infection and COVID-19 death: population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform , 2020, medRxiv.

[17]  Jessica K De Freitas,et al.  Coronavirus 2019 and People Living With Human Immunodeficiency Virus: Outcomes for Hospitalized Patients in New York City , 2020, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

[18]  S. Fuchs,et al.  The need for reappraisal of AIDS score weight of Charlson comorbidity index. , 2007, Journal of clinical epidemiology.

[19]  Esteban Walker,et al.  Regression Modeling Strategies , 2003, Technometrics.

[20]  L. Real,et al.  Incidence of and factors associated with SARS-CoV-2 infection among people living with HIV in Southern Spain , 2021 .

[21]  S. Braunstein,et al.  Coronavirus Disease 2019 (COVID-19) Infection Among People With Human Immunodeficiency Virus in New York City: A Population-Level Analysis of Linked Surveillance Data , 2021 .

[22]  Who Consultation on Obesity.  Obesity: preventing and managing the global epidemic. Report of a WHO consultation. , 2000, World Health Organization technical report series.

[23]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.